Physician profile
Ashley C Royce
NPI 1437336856
$3,350.60
in general payments reported to CMS, 2019-2025
22 companies · $711 in 2025
The $711 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $166 · 2021: $301 · 2022: $659 · 2023: $506 · 2024: $759 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,976.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $609.09 | 2019-2023 | |
| Alcon Vision LLC | $527.74 | 2022-2025 | Clareon, Clareon Panoptix Pro, Tryptyr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $295.78 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $270.14 | 2021-2025 | |
| Bausch & Lomb Americas INC. | $266.12 | 2023-2025 | Xiidra, Miebo, Prolensa |
| Abbvie INC. | $168.30 | 2022-2024 | Durysta |
| Tarsus Pharmaceuticals, INC. | $167.58 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $138.61 | 2024-2025 | Tyrvaya |
| Dompe US, INC. | $134.81 | 2023-2025 | Oxervate |
| Glaukos Corporation | $125.66 | 2022 | |
| Harrow Eye, LLC | $125.45 | 2024-2025 | Vevye |
| Horizon Therapeutics Plc | $123.11 | 2022 | |
| Astellas Pharma US INC | $120.16 | 2023 | |
| Aerie Pharmaceuticals, INC. | $60.96 | 2019-2020 | |
| Genzyme Corporation | $50.00 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $38.64 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $38.39 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $22.26 | 2021 | |
| Eyevance Pharmaceuticals LLC | $20.50 | 2022 | |
| Biotissue Holdings INC. | $19.34 | 2024 | |
| Omeros Corporation | $16.00 | 2019 | |
| Shire North American Group INC | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Royce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.